"药物经济学不仅要关注药品价格本身，还要关注药品对其他费用的节约，处方药物与其他药物进行对 比。不仅要看比对药品的直接效果和成本费用，还要综合考虑是否缩短住院时间、提高患者的感受状 态、以及是否减少副作用和并发症等方面的问题。"北京大学全球健康发展研究院院长刘国恩呼吁，中 国推进药物经济学的应用发展，其紧迫性和重要性都非常显著。 近日，第十九届中国药学发展奖颁奖典礼暨医药创新发展大会评选出"特别贡献奖"5位，分别授予陆军 军医大学邹全明教授、北京大学第一医院霍勇教授、中国药科大学郝海平教授、北京大学全球健康发展 研究院刘国恩教授、耶鲁大学医学院郑永齐教授。 刘国恩凭借在药物经济学领域的开创性研究与政策实践贡献，荣获"药学发展奖·特别贡献奖"。原国务 委员、第十一届全国人大常委会副委员长陈至立与中国工程院院士、天津中医药大学名誉校长张伯礼为 大会颁奖。 中国药学发展奖是经中国科协批准、国家民政部备案，由中国科学技术发展基金会药学发展基金委员会 于1994年设立的全国性医药学奖项，也是国家科技部首批批准的奖励人物的医药学奖项。自1994年6月 在国家科技部奖励办公室设立以来，奖励在医药卫生领域中取得原始性突破创新 ...

Group 1: Medical Insurance Development - The National Medical Insurance Administration emphasizes empowering the pharmaceutical industry and implementing measures to support high-quality development of innovative drugs [1][2] - By mid-2025, significant progress is expected in medical insurance, including an increase in the number of insured individuals under maternity insurance to 253 million and total maternity insurance benefits expenditure reaching 67.832 billion [1] - The meeting highlights the need for a comprehensive adjustment of the national medical insurance drug catalog and the establishment of a commercial health insurance innovative drug catalog [2] Group 2: Maternity Insurance and Long-term Care - The meeting encourages regions to include flexible employment workers, migrant workers, and new employment forms in maternity insurance coverage, while also exploring basic service packages for prenatal check-ups [3] - There is a push for the implementation of long-term care insurance, with a focus on planning and supporting long-term care services at the community level [3] - The meeting calls for the integration of long-term care services with commercial insurance products to enhance accessibility and suitability of care [3] Group 3: Digital Transformation in Medical Insurance - The meeting aims to transition the medical insurance system from passive payment to proactive empowerment, focusing on health investment rather than just disease compensation [3] - There is an emphasis on promoting research in disease prediction modeling, pharmacoeconomics, and disease attribution analysis in collaboration with medical institutions and research organizations [3] - The integration of technology in medical insurance is encouraged to foster new medical services, AI health management, and smart elderly care [3]